ArticleHealth services research2010
Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
Article in Health services research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review.Journal of managed care & specialty pharmacy · 2023Pooled it
- A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions.European journal of hospital pharmacy : science and practice · 2019Pooled it
- Financial Toxicity Associated with Biological Medicines: A Scoping Review.Clinical pharmacology and therapeutics · 2026Article
- Disparities in the access to and use of biologic and targeted synthetic treatments in patients with inflammatory rheumatic and musculoskeletal diseases: a scoping review.EULAR rheumatology open · 2026Article
- "You Have to Rob Peter to Pay Paul So Your Kid Can Breathe": Using Qualitative Methods to Characterize Trade-Offs and Economic Impact of Asthma Care Costs.Medical care · 2023Article
- Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.Exploratory research in clinical and social pharmacy · 2023Article
- Socioeconomic Status and Medication Use in Rheumatoid Arthritis: A Scoping Review.Arthritis care & research · 2023Article
- Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis.JAMA network open · 2021Article
- The distributive fairness of out-of-pocket healthcare expenditure in the Russian Federation.International journal of health economics and management · 2020Article
- The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.American health & drug benefits · 2019Article
- Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.Health services research · 2018Article
- The Price Elasticity of Specialty Drug Use: Evidence from Cancer Patients in Medicare Part D.Forum for health economics & policy · 2017Article
- Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.Journal of managed care & specialty pharmacy · 2017Article
- Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis.American health & drug benefits · 2017Article
- Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.American health & drug benefits · 2017Article
- High Out-of-Pocket Medical Spending among the Poor and Elderly in Nine Developed Countries.Health services research · 2016Article
- Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.Journal of the American Academy of Dermatology · 2016Article
- Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.Journal of managed care & specialty pharmacy · 2016Article
- The financial burden of out-of-pocket expenses in the United States and Canada: How different is the United States?SAGE open medicine · 2016Article
- Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo examine the impact of benefit generosity and household health care financial burden on the demand for specialty drugs in the treatment of rheumatoid arthritis (RA). DATA SOURCES/STUDY
settingEnrollment, claims, and benefit design information for 35 large private employers during 2000-2005. STUDY
designWe estimated multivariate models of the effects of benefit generosity and household financial burden on initiation and continuation of biologic therapies. DATA EXTRACTION
methodsWe defined initiation of biologic therapy as first-time use of etanercept, adalimumab, or infliximab, and we constructed an index of plan generosity based on coverage of biologic therapies in each plan. We estimated the household's burden by summing up the annual out-of-pocket (OOP) expenses of other family members. PRINCIPAL
findingsBenefit generosity affected both the likelihood of initiating a biologic and continuing drug therapy, although the effects were stronger for initiation. Initiation of a biologic was lower in households where other family members incurred high OOP expenses.
conclusionsThe use of biologic therapy for RA is sensitive to benefit generosity and household financial burden. The increasing use of coinsurance rates for specialty drugs (as under Medicare Part D) raises concern about adverse health consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.